Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.40 |
| ▸ | TAF1 | P21675 | 3/20 | 0.38 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | HTR3A | P46098 | 4/20 | 0.37 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27186134 | 0.86 | BRD9 (0.41) | BRD9TAF1CECR2BRD4BRD7 | |
| SCHEMBL29844397 | 0.85 | BTK (0.41) | BRD9TAF1CECR2BRD4JAK2 | |
| SCHEMBL27186378 | 0.76 | SOS1 (0.46) | — | |
| SCHEMBL29844104 | 0.76 | SOS1 (0.46) | — | |
| SCHEMBL27186376 | 0.76 | SOS1 (0.46) | — | |
| SCHEMBL27186210 | 0.73 | IRAK4 (0.35) | HTR3ATP53IRAK4 | |
| SCHEMBL31541806 | 0.72 | SMN1; SMN2 (0.38) | BRD4HTR3ATP53IRAK4 | |
| SCHEMBL20688004 | 0.72 | ALDH1A1 (0.42) | — | |
| SCHEMBL27186295 | 0.71 | PIM3 (0.39) | BRD9TAF1CECR2BRD4PIM1 | |
| SCHEMBL25431879 | 0.71 | CA12 (0.38) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-117651701-A | Novel substituted bicyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2022187266-A1 | NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | BRD9 907/4885TAF1 1821/4885CECR2 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.